Literature DB >> 33528622

Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.

Sietse M Aukema1,2, Giorgio A Croci3,4, Reiner Siebert5,6, Wolfram Klapper7, Susanne Bens8, Kathrin Oehl-Huber8, Rabea Wagener8,9, German Ott10, Andreas Rosenwald11, Philip M Kluin12, Eva van den Berg13, Anneke G Bosga-Bouwer13, Mels Hoogendoorn14, Eva Hoster15,16, Iris Bittmann17, Inga Nagel18,19, Eva M Murga Penas18, Markus Kreuz20, Julia Bausinger8, Wilfried Belder21, Ilske Oschlies3, Martin J S Dyer22, Sandrine Jayne22.   

Abstract

Chromosomal breakpoints involving the MYC gene locus, frequently referred to as MYC rearrangements (MYC - R+), are a diagnostic hallmark of Burkitt lymphoma and recurrent in many other subtypes of B-cell lymphomas including follicular lymphoma, diffuse large B-cell lymphoma and other high-grade B-cell lymphomas and are associated with an aggressive clinical course. In remarkable contrast, in MCL, only few MYC - R+ cases have yet been described. In the current study, we have retrospectively analysed 16 samples (MYC - R+, n = 15, MYC - R-, n = 1) from 13 patients and describe their morphological, immunophenotypic and (molecular) genetic features and clonal evolution patterns. Thirteen out of fifteen MYC - R+ samples showed a non-classical cytology including pleomorphic (centroblastic, immunoblastic), anaplastic or blastoid. MYC translocation partners were IG-loci in 4/11 and non-IG loci in 7/11 analysed cases. The involved IG-loci included IGH in 3 cases and IGL in one case. PAX5 was the non-IG partner in 2/7 patients. The MYC - R+ MCL reported herein frequently displayed characteristics associated with an aggressive clinical course including high genomic-complexity (6/7 samples), frequent deletions involving the CDKN2A locus (7/10 samples), high Ki-67 proliferation index (12/13 samples) and frequent P53 expression (13/13 samples). Of note, in 4/14 samples, SOX11 was not or only focally expressed and 3/13 samples showed focal or diffuse TdT-positivity presenting a diagnostic challenge as these features could point to a differential diagnosis of diffuse large B-cell lymphoma and/or lymphoblastic lymphoma/leukaemia.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Blastoid; CDKN2A; Clonal evolution; MCL; MYC; Mantle cell lymphoma; P53; SOX11; TP53; TdT; Terminal deoxynucleotidyl transferase

Mesh:

Substances:

Year:  2021        PMID: 33528622     DOI: 10.1007/s00428-021-03022-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  37 in total

1.  C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?

Authors:  Lesley Christie; Neil Kernohan; David Levison; Mark Sales; Joan Cunningham; Karen Gillespie; Paul Batstone; David Meiklejohn; John Goodlad
Journal:  Leuk Lymphoma       Date:  2008-03

2.  MYC expression and translocation analyses in low-grade and transformed follicular lymphoma.

Authors:  Sietse M Aukema; Roel van Pel; Inga Nagel; Susanne Bens; Reiner Siebert; Stefano Rosati; Eva van den Berg; Anneke G Bosga-Bouwer; Robby E Kibbelaar; Mels Hoogendoorn; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Philip M Kluin; Marcel Nijland
Journal:  Histopathology       Date:  2017-10-17       Impact factor: 5.087

Review 3.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

4.  Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.

Authors:  Zhihong Hu; L Jeffrey Medeiros; Zi Chen; Weina Chen; Shaoying Li; Sergej N Konoplev; Xinyan Lu; Lan V Pham; Ken H Young; Wei Wang; Shimin Hu
Journal:  Am J Surg Pathol       Date:  2017-02       Impact factor: 6.394

Review 5.  Double-hit B-cell lymphomas.

Authors:  Sietse M Aukema; Reiner Siebert; Ed Schuuring; Gustaaf W van Imhoff; Hanneke C Kluin-Nelemans; Evert-Jan Boerma; Philip M Kluin
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

6.  B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Authors:  Beiying Dai; Michael Grau; Mélanie Juilland; Pavel Klener; Elisabeth Höring; Jan Molinsky; Gisela Schimmack; Sietse M Aukema; Eva Hoster; Niklas Vogt; Annette M Staiger; Tabea Erdmann; Wendan Xu; Kristian Erdmann; Nicole Dzyuba; Hannelore Madle; Wolfgang E Berdel; Marek Trneny; Martin Dreyling; Korinna Jöhrens; Peter Lenz; Andreas Rosenwald; Reiner Siebert; Alexandar Tzankov; Wolfram Klapper; Ioannis Anagnostopoulos; Daniel Krappmann; German Ott; Margot Thome; Georg Lenz
Journal:  Blood       Date:  2016-11-18       Impact factor: 22.113

7.  IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.

Authors:  Rabea Wagener; Cristina López; Kortine Kleinheinz; Julia Bausinger; Sietse M Aukema; Inga Nagel; Umut H Toprak; Julian Seufert; Janine Altmüller; Holger Thiele; Christof Schneider; Julia Kolarova; Jeongbin Park; Daniel Hübschmann; Eva M Murga Penas; Hans G Drexler; Andishe Attarbaschi; Randi Hovland; Eigil Kjeldsen; Michael Kneba; Udo Kontny; Laurence de Leval; Peter Nürnberg; Ilske Oschlies; David Oscier; Brigitte Schlegelberger; Stephan Stilgenbauer; Wilhelm Wössmann; Matthias Schlesner; Birgit Burkhardt; Wolfram Klapper; Elaine S Jaffe; Ralf Küppers; Reiner Siebert
Journal:  Blood       Date:  2018-10-03       Impact factor: 22.113

8.  Double-Hit and Triple-Hit Follicular Lymphoma.

Authors:  Jessica B Ziemba; Zena Wolf; Matthew Weinstock; Saja Asakrah
Journal:  Am J Clin Pathol       Date:  2020-02-29       Impact factor: 2.493

Review 9.  Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!

Authors:  Martin Dreyling; Wolfram Klapper; Simon Rule
Journal:  Blood       Date:  2018-11-01       Impact factor: 22.113

10.  Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma.

Authors:  Cristina López; Kortine Kleinheinz; Sietse M Aukema; Marius Rohde; Stephan H Bernhart; Daniel Hübschmann; Rabea Wagener; Umut H Toprak; Francesco Raimondi; Markus Kreuz; Sebastian M Waszak; Zhiqin Huang; Lina Sieverling; Nagarajan Paramasivam; Julian Seufert; Stephanie Sungalee; Robert B Russell; Julia Bausinger; Helene Kretzmer; Ole Ammerpohl; Anke K Bergmann; Hans Binder; Arndt Borkhardt; Benedikt Brors; Alexander Claviez; Gero Doose; Lars Feuerbach; Andrea Haake; Martin-Leo Hansmann; Jessica Hoell; Michael Hummel; Jan O Korbel; Chris Lawerenz; Dido Lenze; Bernhard Radlwimmer; Julia Richter; Philip Rosenstiel; Andreas Rosenwald; Markus B Schilhabel; Harald Stein; Stephan Stilgenbauer; Peter F Stadler; Monika Szczepanowski; Marc A Weniger; Marc Zapatka; Roland Eils; Peter Lichter; Markus Loeffler; Peter Möller; Lorenz Trümper; Wolfram Klapper; Steve Hoffmann; Ralf Küppers; Birgit Burkhardt; Matthias Schlesner; Reiner Siebert
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

View more
  2 in total

1.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Hematolymphoid Proliferations and Neoplasia.

Authors:  Judith A Ferry
Journal:  Head Neck Pathol       Date:  2022-03-21

Review 2.  How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.

Authors:  José Cabeçadas; Victor E Nava; Joao L Ascensao; Maria Gomes da Silva
Journal:  Curr Oncol       Date:  2021-11-11       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.